Patents Assigned to Amgen
  • OB fusion protein compositions and methods
    Patent number: 8080254
    Abstract: The present invention relates to Fc-OB fusion protein compositions, methods of preparation of such compositions and uses thereof. In particular, the present invention relates to a genetic or chemical fusion protein comprising the Fc immunoglobulin region, derivative or analog fused to the N-terminal portion of the OB protein, derivative or analog.
    Type: Grant
    Filed: September 22, 2006
    Date of Patent: December 20, 2011
    Assignee: Amgen, Inc.
    Inventors: Michael B. Mann, Randy Ira Hecht, Mary Ann Pellymounter, Christopher Francis Toombs
  • Human monoclonal antibodies to activin receptor-like kinase-1
    Patent number: 8080646
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: December 20, 2011
    Assignees: Amgen Fremont, Inc., Pfizer Inc.
    Inventors: Michael Aidan North, Karin Kristina Amundson, Vahe Bedian, Shelly Sims Belouski, Dana Dan Hu-Lowe, Xin Jiang, Shannon Marie Karlicek, Sirid Aimee Kellerman, James Arthur Thomson, Jianying Wang, Grant Raymond Wickman, Jingchuan Zhang
  • S1P receptor modulating compounds and use thereof
    Patent number: 8080542
    Abstract: The present invention relates to amides that have activity as SIP receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: December 20, 2011
    Assignees: Amgen, Inc., Epix Pharmaceuticals, Inc.
    Inventors: Susana C. Neira, Xiang Yu, Roland Burli, Victor Cee, Brian Lanman
  • Pyrazolo-pyridinone derivatives and methods of use
    Patent number: 8080546
    Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of pro-inflammatory cytokine mediated diseases, and in particular, p38 activity mediated inflammation and related conditions. The compounds have a general Formula I wherein A1, A2, A3, A4, A5, R1, R2 and R3 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of inflammatory diseases including rheumatoid arthritis, psoriasis and other disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: December 20, 2011
    Assignee: Amgen Inc.
    Inventors: Liping H. Pettus, Andrew Tasker, Shimin Xu, Ryan Wurz
  • ANTIBODIES TO THYMIC STROMAL LYMPHOPOIETIN RECEPTOR MOLECULES AND USES THEREOF
    Publication number: 20110305705
    Abstract: The present invention provides Thymic Stromal Lymphopoietin Receptor (TSLPR) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TSLPR polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with TSLPR polypeptides.
    Type: Application
    Filed: June 8, 2011
    Publication date: December 15, 2011
    Applicant: AMGEN INC.
    Inventors: Christiaan M. Saris, Ming-Shi Chang
  • EPITOPES
    Publication number: 20110305702
    Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.
    Type: Application
    Filed: April 28, 2011
    Publication date: December 15, 2011
    Applicants: AMGEN INC., UCB PHARMA S.A.
    Inventors: HSIENG S. LU, CHRISTOPHER J. PASZTY, MARTYN KIM ROBINSON, ALISTAIR J. HENRY, KELLY SUE WARMINGTON, JOHN LATHAM, ALASTAIR LAWSON, DAVID G. WINKLER, AARON GEORGE WINTERS
  • Dipeptidyl peptidase-IV inhibitors
    Patent number: 8076330
    Abstract: The present invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitor compounds. The present invention also provides synthetic methods for preparation of such compounds, methods of inhibiting DPP-IV using such compounds and pharmaceutical formulations containing them for treatment of DPP-IV mediated diseases, in particular, Type-2 diabetes.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: December 13, 2011
    Assignee: Amgen Inc.
    Inventors: Heiko Kroth, Tim Feuerstein, Frank Richter, Jürgen Boer, Michael Essers, Bert Nolte, Matthias Schneider, Matthias Hochgürtel, Fritz-Frieder Frickel, Arthur G. Taveras, Christoph Steeneck
  • AURORA KINASE MODULATORS AND METHODS OF USE
    Publication number: 20110301162
    Abstract: The present invention relates to chemical compounds having a general formula I wherein A1-6, L1, R1, R4-6 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinase proteins. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds and methods of treating disease states related to the activity of Aurora kinase.
    Type: Application
    Filed: August 4, 2009
    Publication date: December 8, 2011
    Applicant: AMGEN INC.
    Inventors: Holly L. Deak, Stephanie D. Geuns-Meyer, Jason Brooks Human, Matthew W. Martin, Isaac Marx
  • Tumor endothelial marker 5? molecules and uses thereof
    Patent number: 8071372
    Abstract: The present invention provides Tumor Endothelial Marker 5? (TEM5?) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TEM5? polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, or prevention of diseases, disorders, and conditions associated with TEM5? polypeptides.
    Type: Grant
    Filed: August 9, 2010
    Date of Patent: December 6, 2011
    Assignee: Amgen Inc.
    Inventor: Todd Juan
  • PYRAZOLO-PYRIDINONE AND PYRAZOLO-PYRAZINONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF
    Publication number: 20110294805
    Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A1, A2, B, R1, R2, R4, R5, R6 and Z are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of P38 map kinase mediated diseases including rheumatoid arthritis, psoriasis, chronic obstructive pulmonary disease, pain and other inflammatory disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.
    Type: Application
    Filed: August 3, 2011
    Publication date: December 1, 2011
    Applicant: Amgen Inc.
    Inventors: Liping H. PETTUS, Andrew Tasker, Shimin Xu, Ryan Wurz
  • Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
    Patent number: 8067562
    Abstract: The present invention provides novel activin IIB5 receptor polypeptides capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the receptor polypeptides. Compositions and methods for treating muscle-wasting, metabolic and other disorders are also provided.
    Type: Grant
    Filed: October 31, 2006
    Date of Patent: November 29, 2011
    Assignee: Amgen Inc.
    Inventors: HQ Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
  • METHOD OF TREATMENT
    Publication number: 20110287001
    Abstract: The invention provides methods for inducing apoptosis, comprising treatment of a patient with a TNF? inhibitor as well as with an IAP inhibitor and a TRAIL receptor agonist. The methods ameliorate the risk of unwanted effects, thereby resulting in an improved therapeutic index for IAP inhibitors in combination with a TRAIL receptor agonist.
    Type: Application
    Filed: August 5, 2009
    Publication date: November 24, 2011
    Applicants: TETRALOGIC PHARMACEUTICALS, AMGEN INC.
    Inventors: Pamela M. Holland, Julia C. Piasecki, Christopher A. Benetatos, Srinivas K. Chunduru, Mark A. McKinlay
  • Methods For Diagnosing And Monitoring The Progression Of Cancer
    Publication number: 20110287450
    Abstract: Methods for measuring c-Met levels in urine and blood samples are provided. Methods for diagnosis and prognosis evaluation for cancer are also provided.
    Type: Application
    Filed: March 22, 2011
    Publication date: November 24, 2011
    Applicants: Amgen, Inc., The United States of America, as represented by the Secretary, Dept. of Health & Human Service
    Inventors: Donald P. Bottaro, Gagani Athauda, Teresa Lynn Burgess
  • Substituted pyridone compounds and methods of use
    Patent number: 8063055
    Abstract: The present invention comprises a new class of compounds capable of modulating the c-kit receptor and, accordingly, useful for treatment of c-kit mediated diseases, including various inflammatory, fibrotic and/or mast cell mediated diseases such as mastocytosis. The compounds have a general Formula I wherein A0-3 and R1-6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of c-kit mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.
    Type: Grant
    Filed: February 23, 2010
    Date of Patent: November 22, 2011
    Assignee: Amgen Inc.
    Inventors: Essa Hu, Jason Brooks Human, Roxanne Kunz, Andrew Tasker, Ryan White
  • HETEROCYCLIC COMPOUNDS AND THEIR USES
    Publication number: 20110281897
    Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity.
    Type: Application
    Filed: July 20, 2011
    Publication date: November 17, 2011
    Applicant: Amgen Inc.
    Inventors: Yi Chen, Timothy D. Cushing, Xiaolin Hao, Xiao He, Andreas Reichelt, Robert M. Rzasa, Jennifer Seganish, Youngsook Shin, Dawei Zhang
  • Pyrido[3,2-d]Pyridazine-2(1H)-One Compounds as p38 Modulators and Methods of Use Thereof
    Publication number: 20110281864
    Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein R1, R2, R3, R4, R5, W and X are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of p38 map kinase mediated diseases including rheumatoid arthritis, psoriasis, chronic obstructive pulmonary disease, pain and other inflammatory disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.
    Type: Application
    Filed: August 26, 2009
    Publication date: November 17, 2011
    Applicant: AMGEN INC.
    Inventors: Liping H. Pettus, Andrew Tasker, Bin Wu
  • NOVEL ACTIVIN RECEPTOR AND USES THEREOF
    Publication number: 20110281796
    Abstract: The present invention provides novel activin IIB5 receptor polypeptides capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the receptor polypeptides. Compositions and methods for treating muscle-wasting, metabolic and other disorders are also provided.
    Type: Application
    Filed: July 25, 2011
    Publication date: November 17, 2011
    Applicant: Amgen Inc.
    Inventors: HQ Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
  • Substituted pyridinecarboxamides for the treatment of cancer
    Patent number: 8058445
    Abstract: Selected pyridine carboxamide compounds of Formula XI are effective for treatment of diseases and other maladies or conditions involving, cancer and the like.
    Type: Grant
    Filed: September 23, 2005
    Date of Patent: November 15, 2011
    Assignee: Amgen Inc.
    Inventor: Andrew Tasker
  • Polynucleotides encoding heavy and light chains of antibodies to OPGL
    Patent number: 8058418
    Abstract: Compositions comprising polynucleotides encoding heavy and light chains of antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of making such antibodies are described.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: November 15, 2011
    Assignees: Amgen Inc., Amgen Fremont Inc.
    Inventors: William J. Boyle, Francis H. Martin, Jose R. Corvalan, C. Geoffrey Davis
  • Modified G-CSF polypeptide
    Patent number: 8058398
    Abstract: The present invention relates to granulocyte colony-stimulating factor (“G-CSF”) hybrid molecules which retain the internal core helices of G-CSF. Also provided are pharmaceutical compositions containing hybrid molecules.
    Type: Grant
    Filed: April 25, 2005
    Date of Patent: November 15, 2011
    Assignee: Amgen Inc.
    Inventor: Timothy D. Osslund